Clinical trials: Anti-Retroviral Agents
HIV Infections
HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study
This study evaluated the safety, immunogenicity, and preliminary assessment of efficacy of a novel vaccine encoding conserved elements (CE) of the HIV-1 Gag core protein, p24Gag, as a therapeutic vaccine in HIV-1 infected persons…
- Trial name
- NCT03560258
- Testing
- p24CE1/2 pDNA vaccine, p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine, Full-length p55^gag pDNA vaccine
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 45 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus (HIV)
Antiretroviral Treatment Strategies in Relation to Adherence, Resistance and Virological Treatment Failure
This project aims to assess different antiretroviral treatment strategies, optimally controlled and conventional, in relation to drug resistance and virological treatment failure.
- Trial name
- DotArv (NCT01433601)
- Testing
- Enhanced Treatment Support (ETS)
- Where
- Vietnam
- Volunteers
- 640 people
- Sponsor
- Karolinska Institutet
HIV Infections
Safety and Effectiveness of PEG-Intron in HIV-Infected Patients
The purpose of this study is to see if it is effective to give PEG-Intron (PEG-IFN) to HIV-infected patients who are not doing well with their current anti-HIV drug combination (HAART).
- Trial name
- NCT00005012
- Testing
- Peginterferon alfa-2b
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 250 people
- Sponsor
- Schering-Plough
HIV Infections, Renal Transplant Rejection
Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant
This is an open-label study, where participants will be switched from their current HIV medication to the study drug, BIC/F/TAF. Open-label means both the investigator and the participant will know what drug will be given.
- Trial name
- NCT04530630
- Testing
- BIC/F/TAF 50Mg-200Mg-25Mg Tablet
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
HIV-1-infection
Dolutegravir/Lamivudine in Treatment-Naïve Pregnant Women
Protocol Number: FH-94 Study Objetives: Primary: To evaluate the virological response to Dolutegravir/Lamivudine in naive pregnant women with HIV who are starting antiretroviral therapy and vertical transmission in exposed…
- Trial name
- PREDUAL (NCT07616739)
- Testing
- Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO], TDF/XTC or TAF/FTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine)
- Where
- 10 sites in Argentina, Brazil
- Volunteers
- 210 people
- Sponsor
- Fundación Huésped
HIV-1 Infection
High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART
This study was done with people who were infected with HIV and needed to start treatment for their HIV disease. The purpose of this study is to see if taking vitamin D and calcium will help prevent the bone loss that sometimes…
- Trial name
- NCT01403051
- Testing
- EFV/FTC/TDF, Calcium Carbonate, Vitamin D3
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 167 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Hiv
Postpartum Adherence Clubs for Antiretroviral Therapy
South Africa is implementing the policy of universal initiation of lifelong antiretroviral therapy (ART) in all HIV-infected pregnant women regardless of CD4 cell count or disease stage ("Option B+").
- Trial name
- PACART (NCT03200054)
- Testing
- Adherence Clubs
- Where
- South Africa
- Volunteers
- 412 people
- Sponsor
- University of Cape Town
Human Immunodeficiency Virus
Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy
A randomised controlled trial to investigate three methods to reduce early mortality in adults, adolescents and children aged 5 years or older starting antiretroviral therapy (ART) with severe immuno-deficiency.
- Trial name
- REALITY (NCT01825031)
- Testing
- Raltegravir, Fluconazole, Azithromycin
- Where
- 8 sites in Kenya, Malawi and 2 more
- Volunteers
- 1,805 people
- Sponsor
- Anna Griffiths, MRC
HIV - Human Immunodeficiency Virus
Immunotherapy With Glatiramer Acetate in PLWHIV in Poor Immunological Responders on Antiretroviral Therapy
The purpose of this trial is to evaluate the immunomodulatory effects of glatiramer acetate (GA) in improving the recovery of CD4 T cells and the CD4/CD8 ratio in people living with HIV (PLWHIV) who have poor immune recovery and…
- Trial name
- GEODE (NCT07851337)
- Testing
- - Study treatment arm group (Arm A): GLATIRAMER VIATRIS 40mg/ml
- Volunteers
- 36 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV, Human Immunodeficiency Virus
Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study
The purpose of this study is to determine the safety and bioactivity of an herbal supplement called "kansui," which contains several active ingredients such as ingenols that may have a role in helping clear HIV from the body.
- Trial name
- NCT02531295
- Testing
- Euphorbia kansui extract powder prepared as tea
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, San Francisco
HIV-1-infection, Antiretroviral Therapy
Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection (Simpl'HIV)
The purpose of this study is to evaluate whether maintenance antiretroviral therapy could be simplified to DTG + FTC dual therapy and/or patient-centered monitoring once virological suppression is achieved.
- Conditions
- HIV-1-infection, Antiretroviral Therapy, Maintenance Therapy
- Trial name
- Simpl'HIV (NCT03160105)
- Testing
- Switch to DTG + FTC, Patient-centered monitoring
- Where
- 7 sites in Switzerland
- Volunteers
- 186 people
- Sponsor
- Calmy Alexandra
HIV Infections
Telephone Support to Improve Adherence to Anti-HIV Medications
This study tested a system of nursing telephone support to determine if it improves adherence to antiretroviral therapy (ART) in at-risk, treatment-experienced people.
- Trial name
- NCT00988442
- Testing
- Enhanced nursing telephone support, Standard care
- Where
- 16 sites in United States
- Volunteers
- 59 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infection
A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine
This is a pilot study to evaluate the ability of highly active antiretroviral therapy administered to children with HIV-1 infection to effect immunoreconstitution in children with HIV-1 infection.
- Trial name
- NCT00001688
- Testing
- Ritonavir, Nevirapine, Stavudine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
The First Long-Acting Injectable Regimen (FLAIR) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult participants whose virus is virologically suppressed on an integrase inhibitor…
- Trial name
- NCT02938520
- Testing
- Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA)
- Where
- 108 sites in United States, Canada and 9 more
- Volunteers
- 631 people
- Sponsor
- ViiV Healthcare
HIV, HIV Infections
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir…
- Trial name
- NCT01780506
- Testing
- E/C/F/TAF, E/C/F/TDF
- Where
- 117 sites in United States, Australia and 10 more
- Volunteers
- 872 people
- Sponsor
- Gilead Sciences
HIV Infections, HIV-1
TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.
The purpose of this trial is to compare the effectiveness, safety and tolerability of TMC278 given at a dose of 25 mg once daily versus efavirenz (EFV) at a dose of 600 mg once daily, when combined with a fixed background regimen…
- Conditions
- HIV Infections, HIV-1, Human Immunodeficiency Virus Type 1
- Trial name
- NCT00540449
- Testing
- TMC278, Efavirenz
- Where
- 92 sites in United States, Argentina and 18 more
- Volunteers
- 694 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Antiretroviral Therapy (ART) Adherence
Optimizing Care Delivery to Support Reengagement in PLWH Returning to HIV Care After Treatment Lapses in Zambia
1.0 Introduction The scale-up of human immunodeficiency virus (HIV) treatment services has expanded rapidly in Zambia, facilitated by evolution of the HIV response from centralized services to decentralized care and now towards…
- Trial name
- Reengagement (NCT06803316)
- Where
- Zambia
- Volunteers
- 658 people
- Sponsor
- Centre for Infectious Disease Research in Zambia
HIV Coinfection
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
To describe liver enzyme elevations in patients who are coinfected with HIV and either Hepatitis C (HCV) and/or Hepatitis B (HBV) receiving maraviroc or placebo in combination with their current suppressive anti-HIV drug therapy.
- Trial name
- NCT01327547
- Testing
- Maraviroc
- Where
- 48 sites in United States, Czechia and 7 more
- Volunteers
- 138 people
- Sponsor
- ViiV Healthcare
Immunodeficiency Virus Type 1, Human
A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects
The purpose of this study is to demonstrate non-inferiority in efficacy of a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus Darunavir/Cobicistat (DRV/COBI) FDC…
- Trial name
- NCT02431247
- Testing
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC, DRV/COBI FDC, FTC/TDF FDC
- Where
- 80 sites in United States, Belgium and 8 more
- Volunteers
- 725 people
- Sponsor
- Janssen Sciences Ireland UC
HIV-1 Infection
Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
This study will evaluate the safety, tolerability, antiretroviral activity, and pharmacokinetics of 3 doses of islatravir (MK-8591) in combination with doravirine (DOR) and lamivudine (3TC) administered to antiretroviral…
- Trial name
- NCT03272347
- Testing
- Islatravir, Doravirine, Lamivudine
- Where
- 26 sites in United States, Chile and 2 more
- Volunteers
- 123 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.